医学英文文献及汉语翻译.doc

Bio Med Central Page 1 of 7 (page number not for citation purposes) Radiation Oncology Research Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme Clifton D Fuller1,2,3, Mehee Choi1, Britta Forthuber4, Samuel J Wang3, Nancy Rajagiriyil5, Bill J Salter6 and Martin Fuss*3,1 Address: 1Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, 2Graduate Division of Radiological Sciences, Department of Radiology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, 3Department of Radiation Medicine, Oregon Health Science University, Portland, OR, USA, 4Department of Radio-Oncology, University of Innsbruck, Innsbruck, Austria, 5Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX, USA and 6Department of Radiation Oncology, University of Utah Health Sciences Center, Salt Lake City, UT, USA Email: Clifton D Fuller - fullercd@; Mehee Choi - choim@; Britta Forthuber - Britta.Forthuber@uibk.ac.at; Samuel J Wang - wangsa@; Nancy Rajagiriyil - nrajagiriyil@; Bill J Salter - bill.salter@; Martin Fuss* - fussm@ * Corresponding author Abstract Background: Intensity-modulated radiation therapy (IMRT) affords unparalleled capacity to deliver conformal radiation doses to tumors in the central nervous system. However, to date, there are few reported outcomes from using IMRT, either alone or as a boost technique, for standard fractionation radiotherapy for glioblastoma multiforme (GBM). Methods: Forty-two patients were treated with IMRT alone (72%) or as a boost (28%) after 3- dimensional conformal radiation therapy (3D-CRT). Thirty-three patients with primary disease and 9 patients with recurrent tumors were included. Thirty-four patients (81%) had surgery, with gross tumor resection in 13 patients (36%); 22 patients (53%) received chemo-radiotherapy. The median tota